PERIOPERATIVE IMFINZI® (DURVALUMAB) PLUS NEOADJUVANT ENFORTUMAB VEDOTIN GRANTED PRIORITY REVIEW IN THE US FOR PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER

Reuters · 1d ago

Please log in to view news